KALA BIO, Inc. (KALA)
NASDAQ: KALA · Real-Time Price · USD
5.73
-0.10 (-1.75%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Company Description
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States.
The company’s product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases.
The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023.
KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
KALA BIO, Inc.
| Country | United States |
| Founded | 2009 |
| IPO Date | Jul 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Todd Bazemore |
Contact Details
Address: 1167 Massachusetts Avenue Arlington, Massachusetts 02476 United States | |
| Phone | 781 996 5252 |
| Website | kalarx.com |
Stock Details
| Ticker Symbol | KALA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001479419 |
| CUSIP Number | 483119103 |
| ISIN Number | US4831192020 |
| Employer ID | 27-0604595 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Todd Bazemore | Interim Chief Executive Officer |
| Dr. R. Kim Brazzell Ph.D. | Head of Research & Development and Chief Medical Officer |
| Dr. Justin Hanes Ph.D. | Founder and Chair of the Scientific Advisory Board |
| Mary Reumuth CPA | Chief Financial Officer and Treasurer |
| Jill S. Steier | Executive Director of Investor Relations and Corporate Communications |
| Vincent Kosewski | Senior Vice President of Manufacturing and Supply Chain Management |
| Darius Kharabi J.D., M.B.A. | Chief Business Officer |
| Dr. Francis S. Mah M.D. | Chief Medical Advisor |
| Josiah Craver | Senior Vice President and Corporate Controller |
| Carl Rennie | Executive Director of Account Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 424B5 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | 8-K | Current Report |
| Feb 4, 2025 | EFFECT | Notice of Effectiveness |
| Feb 4, 2025 | 424B3 | Prospectus |
| Jan 31, 2025 | UPLOAD | Filing |
| Jan 24, 2025 | S-3 | Registration statement under Securities Act of 1933 |